Jill Murphy 

ten23 health, a contract development and manufacturing organization (CDMO), announced a capacity expansion for the manufacture of sterile drug product at its Visp facility, according to a press release.

Due to customer demand for sterile fill and finish services, the expansion will head to VIVA 1, Visp Valais, Switzerland, at a sterile manufacturing facility. Following successful completion of the GMP inspection by Swissmedic and an obtained GMP license, the new storage areas are set to become operational in September 2023. Additionally, the output of ten23’s existing sterile manufacturing facility in Visp will be gradually increased by a further 50% capacity by hiring more staff to operate an additional shift.

According to the press release, further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing. Two additional filling lines for sterile commercial supplies of ready-to-use syringes, cartridges, and vials and liquid or freeze-dried clinical and commercial vial supplies will all be a part of VIVA 2. This project is signed for manufacturing in 2024 and 2025.

“We are thrilled to offer our customers additional sterile manufacturing capacity for sophisticated and highly precise Drug Product-presentations such as syringes and cartridges, increased capacity until the two new production lines becoming fully operational.” said Professor Hanns-Christian Mahler, PhD, CEO of ten23 health, in a press release. “With recent demand increases for clinical as well as commercial drug launches, our customers are keen to take advantage of increased capacity from the existing VIVA 1® facility, before the new plant VIVA 2® will be utilized for larger scales.”

Articles

Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.

Ten23 Expands Sterile Manufacturing Capacity at VIVA 1 Facility

Image Credit: Adobe Stock Images/Gorodenkoff

On Aug. 28, 2023, Embark Laboratories announced it has been acquired by Novo Nordisk, including its lead metabolic program, in addition to entering a three-year research and development collaboration to discover and develop novel pharmaceuticals to treat obesity and related comorbidities, according to the press release.

Under the acquisition agreement for Embark Biotech, Novo Nordisk receives the full rights to develop and commercialize the lead program. Additionally, the research and development collaboration with Embark Laboratories provides Novo Nordisk with the option to acquire selected assets based on the Embark Biotech findings across several indications, including obesity and type 2 diabetes, according to the release.

“Novo Nordisk has been engaged in obesity research for 25 years, and we continuously search for new ways to address this serious chronic disease. We are excited about the opportunity to advance Embark Biotech’s lead program and look forward to co-creating novel treatments for cardiometabolic diseases with Embark Laboratories to complement our in-house R&D,” said Brian Finan, vice president of Obesity Research at Novo Nordisk, in a press release.

“There is a clear strategic fit between the novel biology we have discovered and Novo Nordisk’s expertise and focus on developing new drugs in the cardiometabolic space. We are thrilled to pass on the baton for our lead metabolic program to Novo Nordisk. This deal and Embark’s success are direct outcomes of the unique and innovative ecosystem in Denmark that has been cultivated by the BioInnovation Institute and the University of Copenhagen and through initiatives from the Novo Nordisk Foundation and the Innovation Fund Denmark,” said Zach Gerhart-Hines, chief technology officer at Embark Laboratories in the release.

Novo Nordisk receives the full rights to develop and commercialize the lead program.